| 1 |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| 2 |
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016 [J]. J Natl Cancer Cent, 2022, 2(1): 1-9.
|
| 3 |
中国医师协会外科医师分会, 中华医学会外科分会胃肠外科学组, 中华医学会外科分会结直肠外科学组, 等. 中国结直肠癌肝转移诊断和综合治疗指南(V2020) [J]. 中华胃肠外科杂志, 2021, 24(1): 1-13.
|
| 4 |
国家卫生健康委员会. 结直肠癌诊疗规范(2018年版) [J/OL]. 中华消化病与影像杂志(电子版), 2019, 9(3): 118-144.
|
| 5 |
中华医学会肝病学分会. 肝硬化诊治指南[J].中华肝脏病杂志, 2019, 27(11): 846-865.
|
| 6 |
Gunarathne LS, Rajapaksha H, Shackel N, et al. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics [J]. World J Gastroenterol, 2020, 26(40): 6111-6140.
|
| 7 |
Lunova M, Frankova S, Gottfriedova H, et al. Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis [J]. Physiol Res, 2021, 70(4): 563-577.
|
| 8 |
Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis [J]. Lancet, 2021, 398(10308): 1359-1376.
|
| 9 |
Kaps L, Schuppan D. Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers [J]. Cells, 2020, 9(9): 2027.
|
| 10 |
中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年) [J]. 中华肝脏病杂志, 2019, 27(9): 657-667.
|
| 11 |
Barry AE, Baldeosingh R, Lamm R, et al. Hepatic stellate cells and hepatocarcinogenesis [J]. Front Cell Dev Biol, 2020, 8: 709.
|
| 12 |
Wu Y, Cao Y, Xu K, et al. Dynamically remodeled hepatic extracellular matrix predicts prognosis of early-stage cirrhosis [J]. Cell Death Dis, 2021, 12(2): 163.
|
| 13 |
Cao J, Luo SM, Liang L, et al. Effects of parenteral nutrition without and with growth hormone on growth hormone/insulin-like growth factor-1 axis after hepatectomy in hepatocellular carcinoma with liver cirrhosis [J]. JPEN J Parenter Enteral Nutr, 2007, 31(6): 496-501.
|
| 14 |
Anzo M, Cobb LJ, Hwang DL, et al. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression [J]. Cancer Res, 2008, 68(9): 3342-3349.
|
| 15 |
Holdaway IM, Mason BH, Lethaby AE, et al. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer [J]. ANZ J Surg, 2003, 73(11): 905-908.
|
| 16 |
Kasprzak A. Insulin-Like growth factor 1 (IGF-1) signaling in glucose metabolism in colorectal cancer [J]. Int J Mol Sci, 2021, 22(12): 6434.
|
| 17 |
Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling [J]. Oncogene, 2016, 35(20): 2634-44.
|
| 18 |
Lee HK, Lee JH, Kim M, et al. Insulin-like growth factor-1 induces migration and expression of laminin-5 in cultured human corneal epithelial cell [J]. Invest Ophthalmol Vis Sci, 2006, 47(3): 873-882.
|
| 19 |
Livingstone C. IGF2 and cancer [J]. Endocr Relat Cancer, 2013, 20(6): R321-39.
|
| 20 |
Song BC, Chung YH, Kim JA, et al. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study [J]. Cancer, 2001, 91(12): 2386-2393.
|
| 21 |
Feng X, Aleem E, Lin Y, et al. Multiple antitumor effects of picropodophyllin in colon carcinoma cell lines: clinical implications [J]. Int J Oncol, 2012, 40(4): 1251-1258.
|
| 22 |
Kasprzak A, Adamek A. Insulin-like growth factor 2 (IGF2) signaling in colorectal cancer-from basic research to potential clinical applications [J]. Int J Mol Sci, 2019, 20(19): 4915.
|
| 23 |
Lv J, Liu C, Chen FK, et al. M2-like tumour-associated macrophage-secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway [J]. Mol Med Rep, 2021, 24(2): 604.
|
| 24 |
Chen Y, Tian Z. HBV-Induced immune imbalance in the development of HCC [J]. Front Immunol, 2019, 10: 2048.
|
| 25 |
Kuppen PJ, Gorter A, Hagenaars M, et al. Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model [J]. Immunol Rev, 2001, 184: 236-43.
|
| 26 |
Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy [J]. Nat Rev Drug Discov, 2020, 19(3): 200-218.
|
| 27 |
Jiang K, Chen H, Fang Y, et al. Exosomal ANGPTL1 attenuates colorectal cancer liver metastasis by regulating Kupffer cell secretion pattern and impeding MMP9 induced vascular leakiness [J]. J Exp Clin Cancer Res, 2021, 40(1): 21.
|
| 28 |
Chen LM, Fan XG, Ma J, et al. Molecular mechanisms of HBeAg in persistent HBV infection [J]. Hepatol Int, 2017, 11(1): 79-86.
|
| 29 |
Zhang GL, Zhao QY, Xie C, et al. Elevated serum IgG levels positively correlated with IL-27 may indicate poor outcome in patients with HBV-Related acute-on-chronic liver failure [J]. J Immunol Res, 2019, 2019: 1538439.
|
| 30 |
Suga M, Arima K, Yachi A. Detection of IgM, IgA, and IgG antibodies to preS2 antigen in hepatitis B virus infection [J]. Digestion, 1991, 50(3-4): 153-161.
|
| 31 |
Li Q, Lu Q, Zhu MQ, et al. Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure [J]. BMC Gastroenterol, 2020, 20(1): 106.
|
| 32 |
Faille D, Labreuche J, Meseguer E, et al. Endothelial markers are associated with thrombolysis resistance in acute stroke patients [J]. Eur J Neurol, 2014, 21(4): 643-647.
|
| 33 |
Tunçbilek S. Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection [J]. World J Gastroenterol, 2014, 20(20): 6226-6235.
|
| 34 |
Navi BB, Sherman CP, Genova R, et al. Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study [J]. Ann Neurol, 2021, 90(1): 159-169.
|
| 35 |
Sutton CD, O'Byrne K, Goddard JC, et al. Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis [J]. Clin Cancer Res, 2005, 11(18): 6567-6573.
|
| 36 |
Teraoku H, Morine Y, Ikemoto T, et al. Role of thrombospondin-1 expression in colorectal liver metastasis and its molecular mechanism [J]. J Hepatobiliary Pancreat Sci, 2016, 23(9): 565-73.
|
| 37 |
Tokunaga T, Nakamura M, Oshika Y, et al. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer [J]. Br J Cancer, 1999, 79(2): 354-359.
|
| 38 |
Yoshida N, Kinugasa T, Miyoshi H, et al. A high RORγT/CD3 ratio is a strong prognostic factor for postoperative survival in advanced colorectal cancer: analysis of helper T cell lymphocytes (Th1, Th2, Th17 and Regulatory T Cells) [J]. Ann Surg Oncol, 2016, 23(3): 919-9+27.
|
| 39 |
Lee JY, Seo EH, Oh CS, et al. Impact of circulating T helper 1 and 17 cells in the blood on regional lymph node invasion in colorectal cancer [J]. J Cancer, 2017, 8(7): 1249-1254.
|
| 40 |
von Lilienfeld-Toal M, Nattermann J, Feldmann G, et al. Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells [J]. Clin Exp Immunol, 2006, 144(3): 528-33.
|
| 41 |
Xiao L, Cen D, Gan H, et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients [J]. Mol Ther, 2019, 27(6): 1114-1125.
|
| 42 |
Cappuzzello E, Sommaggio R, Zanovello P, et al. Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells [J]. Cytokine Growth Factor Rev, 2017, 36: 99-105.
|
| 43 |
Ewen EM, Pahl JHW, Miller M, et al. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells [J]. Eur J Immunol, 2018, 48(2): 355-365.
|
| 44 |
Van der Meer JMR, Maas RJA, Guldevall K, et al. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells [J]. Cancer Immunol Immunother, 2021, 70(5): 1305-1321.
|
| 45 |
Lusty E, Poznanski SM, Kwofie K, et al. IL-18/IL-15/IL-12 synergy induces elevated and prolonged IFN-γ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation [J]. Mol Immunol, 2017, 88: 138-147.
|
| 46 |
Kondo T, Okabayashi K, Hasegawa H, et al. The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer [J]. Br J Cancer, 2016, 115(1): 34-39.
|
| 47 |
Kanzaki M, Wada J, Nakatsuka A, et al. A case of type 2 diabetes and metastatic liver cancer exhibiting hypercholesterolemia with abnormal lipoprotein [J]. Intern Med, 2012, 51(6): 619-623.
|
| 48 |
Li Y, Su X, Rohatgi N, Zhang Y, et al. Hepatic lipids promote liver metastasis [J]. JCI Insight, 2020, 5(17): e136215.
|
| 49 |
Sun X, Essalmani R, Day R, et al. Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver [J]. Neoplasia, 2012, 14(12): 1122-1131.
|
| 50 |
Kusama T, Mukai M, Iwasaki T, et al. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis [J]. Gastroenterology, 2002, 122(2): 308-317.
|
| 51 |
Ling Y, Yang L, Huang H, et al. Prognostic significance of statin use in colorectal cancer: A systematic review and meta-analysis [J]. Medicine (Baltimore), 2015, 94(25): e908.
|
| 52 |
Verna L, Ganda C, Stemerman MB. In vivo low-density lipoprotein exposure induces intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 correlated with activator protein-1 expression [J]. Arterioscler Thromb Vasc Biol, 2006, 26(6): 1344-1349.
|